Nachrichten zur Eli Lilly & Co. Aktie

Silver Economy Investing: Why the Healthcare Giants Are in Focus

Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep…

Eli Lilly: Novo Nordisk Was Just A Warm-Up

…

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Pill Could Crash the Weight-Loss Party

This dark horse in the weight loss drug race is worth keeping on your watch list.…

GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain

Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.…

Eli Lilly Stock: Next Stop $2,000?

The company is riding an incredible tailwind.…

Eli Lilly loses Supreme Court appeal of $194 million fraud award

Eli Lilly loses Supreme Court appeal of $194 million fraud award…

US Supreme Court turns away Eli Lilly’s challenge to whistleblower law

US Supreme Court turns away Eli Lilly’s challenge to whistleblower law…

US Supreme Court turns away Eli Lillys challenge to whistleblower law

The U.S. Supreme Court declined on Monday to hear a challenge by drugmaker Eli Lilly to a Civil War-era whistleblower…

Novo Nordisks Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says

Novo Nordisks (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline...…

Novo Nordisks Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says

Novo Nordisks (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline...…

Hims And Hers Reshapes Growth With Branded GLP 1s And Eucalyptus Deal

Hims & Hers Health (NYSE:HIMS) is shifting its weight loss offering from compounded GLP-1 drugs to branded medications from partners…

Morgan Stanley flags vital Eli Lilly signal for 2026

Picture a drug so popular that, even in markets where a cheaper generic competitor had just launched, it still grew…

Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lillys Growing Pressure?

NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lillys expanding GLP-1 portfolio threatens its obesity market dominance.…

Should Eli Lilly Investors Worry About Its Newest Rival -- From Within?

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.…

GLP-1 Wars: Winners & Losers

With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1…

Should Hims & Hers Health’s AI and GLP-1 Push Require Action From Hims & Hers Health (HIMS) Investors?

In recent weeks, Hims & Hers Health launched its Labs AI agent to help users interpret biomarker lab results, expanded…

Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

NVO Rallies 21% in a Month: How Should Investors Play the Stock?

Novo Nordisk stock jumps 21% in a month after a Q1 beat and stronger GLP-1 demand, but pricing pressure and…

Hims Labs AI And GLP 1 Push Test Stock Valuation Story

Hims & Hers Health (NYSE:HIMS) has launched Labs AI, an AI care agent that provides users with personalized, clinically vetted…

Eli Lilly: Strong Buy Raised Revenue Guidance By $2 Billion For 2026 And Label Expansions

…

Eli Lilly: Investing US$4.5bn for GLP-1 Medicine Production

Eli Lilly is investing an additional US$4.5bn to expand its Lebanon, Indiana sites for GLP-1 drugs and genetic medicines amid…

Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.

The competition is far behind.…

Eli Lilly Now Has the Worlds Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy?

Mounjaro generated $8.66 billion in sales in the first quarter.…

What the FDAs Latest Proposal Means for Lilly, Novo, and Hims

The FDAs latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would…

Novo and Lilly gain on signs weight-loss pills could expand the market

Early data from weight-loss pills are lifting shares in Novo Nordisk and Eli Lilly as investors bet that easier-to-take drugs…

Eli Lilly stock swings after FDA liver failure report for GLP-1 drug

Eli Lilly (LLY) stock initially sold off on Monday morning, May 4, after the FDA disclosed a liver failure report…

Lilly commits additional $4.5 billion across Indiana manufacturing sites

Eli Lilly said on ?Wednesday it would commit an additional $4.5 billion ?investment across two of its three sites in…

Top Research Reports for Eli Lilly, Western Digital & Vertiv

Eli Lillys strong GLP-1 drug demand and pipeline advances drive growth, while Western Digital and Vertiv ride AI-fueled momentum and…

3 Reasons Its Not Too Late to Buy Eli Lilly Stock

The company still has a strong lead in its core therapeutic area.…

Novo Nordisk’s head start on GLP-1 pills forces investors to rethink Eli Lillys dominance

Early signs from the launch of Novo Nordisks Wegovy pill and Eli Lilly & Co.s Foundayo are making investors rethink…

Whats behind Eli Lillys down-and-up day after last weeks post-earnings surge

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…

Why Eli Lilly stock is down 3% today: FDA adverse event data explained

Why Eli Lilly stock is down 3% today: FDA adverse event data explained…

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage…

Eli Lilly Just Announced Fantastic News for Shareholders

Lillys weight loss drugs have been delivering blockbuster revenue.…

Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?

NVO heads into Q1 with strong GLP-1 drug demand and new Wegovy pill rollout, but pricing pressure, weak guidance and…

Eli Lilly and Company 2026 Q1 - Results - Earnings Call Presentation

…

BofA sees more upside in Eli Lilly stock

Eli Lilly’s first-quarter report gave Wall Street another reason to stay optimistic about one of the market’s biggest pharmaceutical winners,…

Eli Lilly: Buying Opportunity Knocking On The Front Door Again (Rating Upgrade)

…

ResMed (RMD) Q3 2026 Earnings Transcript

Image source: The Motley Fool.DateApr. 30, 2026, 4:30 p.m. ETCall participantsChief Executive Officer — Michael J. FarrellChief Financial Officer —…

Eli Lilly shares surge on a beat-and-raise, proving the stocks swoon was a mistake

Eli Lilly entered Thursday well off its highs. A blowout quarter shows the market got this one wrong.…

Stocks making the biggest moves midday: Blue Owl, Qualcomm, Hertz, Eli Lilly, Meta Platforms, Microsoft & more

Here are the stocks making headlines in midday trading.…

ROUNDUP 2: Überraschend starkes Quartal für Lilly - Ziele angehoben

(Kurs aktualisiert) INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Lilly hat dank der ungebrochen…

Eli Lilly (LLY) – Der Pharmariese entfacht mit Abnehm-Medikamenten neuen Wachstumsrausch und hebt Jahresprognose deutlich an!

Eli Lilly liefert ein Quartal zum Staunen: Umsatz +56 % auf 19,8 Mrd. USD, EPS bei 8,55 USD weit über…

dpa-AFX ProFeed